Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Biosource International -- Ignore unavailable to you. Want to Upgrade?

To: Joe Dancy who wrote (521)	7/13/1998 11:25:00 AM
From: geoffrey Wren	Respond to of 696

Another company on the fast-growing list is IRI. I looked into it a little. From Yahoo: "IRI designs, develops, manufactures and markets in vitro diagnostic (IVD) imaging equipment and special purpose centrifuges and other small instruments for automating microscopic procedures performed in laboratories." From IRI home page: "the industry leading manufacturer of in-vitro laboratory diagnostic imaging automation with products serving hematology, blood collection and coagulation, urinalysis, and genetic analysis." Top line they have been growing. Bottom line they have stagnated. Annual sales of $28m, market cap of $13m. I love seeing a market cap like that. Maybe it is underpriced; maybe it is on its last legs. Maybe it will be bought up by Baxter or J&J or somesuch company. Anyone looked at this co. and have an opinion? I'm thinking of a small position, although I usually stay away from stocks trading at $2/share or less. Geoff Wren

To: Joe Dancy who wrote (521)	7/15/1998 9:09:00 PM
From: Joe Dancy	Read Replies (1) \| Respond to of 696

Earnings to be released after the close Thursday - then conference call. I plan on participating in cc. Two analysts have estimates - consensus 11 cents - one 10 cents and the other 12 cents for Q2. Last quarter (Q1) made 12 cents. Will be interesting to see what revenues look like. I will guess, and this is just a wild guess based on the presentation made a few weeks ago, that we may see 14 cents for the Q2. Then again, all analyst estimates are wild guesses. :) Joe